Narrative review / 2020
Nicotinamide is reviewed as a low-cost, safe, evidence-based treatment for skin cancers, actinic keratosis, and bullous pemphigoid.
This review discusses nicotinamide (niacinamide), a form of vitamin B3 often confused with nicotinic acid (niacin). The authors examine its evidence as a low-cost oral treatment option for actinic keratosis, squamous cell carcinomas, basal cell carcinomas, and bullous pemphigoid. It details nicotinamide's favorable safety profile, distinguishes it from niacin, and addresses barriers to its integration into clinical practice along with practical guidance on recommendations and product availability.
- Study type
- Narrative review
- Who was studied
- Patients with dermatologic conditions considered for nicotinamide treatment
- What was measured
- Efficacy, safety, differences from niacin, and clinical integration
THE PAPER
Nicotinamide: An Update and Review of Safety & Differences from Niacin.
Huber R, Wong A. Skin Therapy Lett, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.